Can a newer MR contrast agent be used to monitor disease progression in muscular dystrophy?
Unger
Evan C
EC
Department of Radiology, University of Arizona, 1501 N Campbell Ave, Tucson, AZ 85724, USA. eunger@radiology.arizona.edu
D000293:Adolescent; D000818:Animals; D002648:Child; D002675:Child, Preschool; D003287:Contrast Media / Q000008:administration & dosage*; D018450:Disease Progression; D000073939:Dysferlin; D016189:Dystrophin / Q000235:genetics; D005466:Fluorocarbons; D006801:Humans; D007089:Image Enhancement / Q000379:methods*; D007091:Image Processing, Computer-Assisted / Q000379:methods*; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008565:Membrane Proteins / Q000172:deficiency / Q000235:genetics; D051379:Mice; D018482:Muscle, Skeletal / Q000473:pathology; D009136:Muscular Dystrophies / Q000175:diagnosis* / Q000235:genetics; D049288:Muscular Dystrophies, Limb-Girdle / Q000175:diagnosis / Q000235:genetics; D009137:Muscular Dystrophy, Animal / Q000175:diagnosis / Q000235:genetics; D020388:Muscular Dystrophy, Duchenne / Q000175:diagnosis / Q000235:genetics; D009942:Organometallic Compounds; D012680:Sensitivity and Specificity
D003287:Contrast Media; C497505:Dysf protein, mouse; D000073939:Dysferlin; D016189:Dystrophin; D005466:Fluorocarbons; D008565:Membrane Proteins; D009942:Organometallic Compounds; C517961:gadofluorine M